ライフサイエンスコーパス: 6-mercaptopurine

1 es S-methylation of thiopurine drugs such as 6-mercaptopurine.

2 mprove on azathioprine but responded well to 6-mercaptopurine.

3 nd 1.27 (95% CI, 0.48-3.39) for azathioprine/6-mercaptopurine.

4 aintenance with ATRA, oral methotrexate, and 6-mercaptopurine.

5 bits a decreased V max and increased K m for 6-mercaptopurine.

6 ome mice were pretreated with leflunomide or 6-mercaptopurine.

7 leukemia (ALL) includes prednisone and oral 6-mercaptopurine.

8 e dose, and all patients received daily oral 6-mercaptopurine.

9 xamined the efficacy of dexamethasone and IV 6-mercaptopurine.

10 ffectiveness of the immuno-suppressive agent 6-mercaptopurine.

11 se, 11), whereas 6-thio NHD(+) (nicotinamide 6-mercaptopurine 5'-dinucleotide, 17) generates a cyclic

12 of their respective substrates, azathioprine/6-mercaptopurine, 5-fluorouracil and sulindac.

13 Although the thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are wel

14 The aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for

15 The thiopurines azathioprine and 6-mercaptopurine (6-MP) are effective immune modulators

16 Azathioprine (AZA) and 6-mercaptopurine (6-MP) are used in pediatric patients w

17 Azathioprine and its metabolite 6-mercaptopurine (6-MP) are well established immunosuppr

18 Clinical experience suggests that 6-mercaptopurine (6-MP) is effective therapy for childre

19 To evaluate potential toxicity of 6-mercaptopurine (6-MP), we reviewed the records of 485

20 among patients treated with azathioprine or 6-mercaptopurine (6-MP).

21 of immunomodulators [azathioprine (AZA), or 6-mercaptopurine (6-MP)] and newer biologic agents (infl

22 6-Mercaptopurine, 6-thioguanine and dasatinib are three

23 oped for the simultaneously determination of 6-mercaptopurine, 6-thioguanine and dasatinib for the fi

24 ed for the selective and precise analysis of 6-mercaptopurine, 6-thioguanine and dasatinib in pharmac

25 data revealed that the electro-oxidation of 6-mercaptopurine, 6-thioguanine and dasatinib is facilit

26 r at pH 8.0, the oxidation peak currents for 6-mercaptopurine, 6-thioguanine and dasatinib were found

27 Compared with 6-mercaptopurine, 6-thioguanine causes excess toxicity w

28 tabolites of three clinically useful agents (6-mercaptopurine, 6-thioguanine, and Abacavir) can inhib

29 Variability in prescribed doses of 6-mercaptopurine (6MP) and lack of adherence to a 6MP tr

30 6-Mercaptopurine (6MP) and methotrexate are the backbone

31 Adequate exposure to oral 6-mercaptopurine (6MP) during maintenance therapy for ch

32 r maintenance phase that includes daily oral 6-mercaptopurine (6MP).

33 igned either 6-thioguanine (750 patients) or 6-mercaptopurine (748 patients) during interim maintenan

34 + azathioprine were superior to azathioprine/6-mercaptopurine: adalimumab (OR, 2.9; 95% CrI, 1.6-5.1)

35 In contrast, pretreatment of mice with 6-mercaptopurine, an inhibitor of de novo purine synthes

36 nd conferred resistance to chemotherapy with 6-mercaptopurine and 6-thioguanine when expressed in ALL

37 the MRP4 drug resistance profile extends to 6-mercaptopurine and 6-thioguanine, two anticancer purin

38 ved in the metabolism of thiopurines such as 6-mercaptopurine and 6-thioguanine.

39 yhan syndrome, the activator of the prodrugs 6-mercaptopurine and allopurinol, and a target for antip

40 (6-TP) medications, including 6-thioguanine, 6-mercaptopurine and azathioprine, commonly used for imm

41 The immunosuppressive agents, azathioprine, 6-mercaptopurine and cyclosporine A, are compatible with

42 hylguanine, 8-azaguanine, 6-thioguanine, and 6-mercaptopurine and do not recognize any of the PurP li

43 1-year treatment period with the following: 6-mercaptopurine and metronidazole [6MP/met] (comparator

44 pite the extensive clinical use and study of 6-mercaptopurine and other purine analogues, the cellula

45 ing some of the antiproliferative effects of 6-mercaptopurine and potentially implicate Nurr1 as a mo

46 ing setons, antibiotics, and azathioprine or 6-mercaptopurine and, in many cases, infliximab.

47 standard dose of thiopurine (azathioprine or 6-mercaptopurine), and patients homozygous for a variant

48 Thiopurines including 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine are effective antican

49 urine drugs, including 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine, are widely employed

50 riptions for 5-aminosalicylates azathioprine/6-mercaptopurine, and corticosteroids were extracted fro

51 icians in optimizing therapeutic response to 6-mercaptopurine, and in identifying individuals at incr

52 It is derived from 6-mercaptopurine, and these two drugs are often used int

53 cytarabine/etoposide; high-dose methotrexate/6-mercaptopurine; and daunorubicin, vincristine, prednis

54 Azathioprine and 6-mercaptopurine are the standard maintenance therapies

55 and Arg221, the only polar amino acids near 6-mercaptopurine, are highlighted as possible participan

56 receptor Nurr1, interestingly, we identified 6-mercaptopurine as a specific activator of this recepto

57 A resolution and the chemotherapeutic agent 6-mercaptopurine at 2.6 A resolution have been determine

58 rential 6-methylmercaptopurine production on 6-mercaptopurine/azathioprine (odds ratio, 3.0; 95% CI,

59 6-Mercaptopurine/azathioprine alone and the addition of

60 corticosteroids alone, 52 patients receiving 6-mercaptopurine/azathioprine alone or with corticostero

61 ry who were receiving corticosteroids and/or 6-mercaptopurine/azathioprine before surgery compared wi

62 ry bowel disease receive corticosteroids and 6-mercaptopurine/azathioprine during elective bowel surg

63 e adjusted odds ratio for patients receiving 6-mercaptopurine/azathioprine for any and major infectio

64 urine/azathioprine alone and the addition of 6-mercaptopurine/azathioprine for patients receiving cor

65 6-mercaptopurine/azathioprine is effective in IBD patien

66 tients receiving neither corticosteroids nor 6-mercaptopurine/azathioprine.

67 hat an active site loop becomes ordered upon 6-mercaptopurine binding.

68 c acid decreases V max and increases K m for 6-mercaptopurine but not K m for S-adenosyl- l-methionin

69 toxic effects of thiopurine prodrugs such as 6-mercaptopurine by methylating them in a reaction using

70 ressant and anticancer drugs azathioprine or 6-mercaptopurine contains 6-thioguanine (6-TG).

71 d assignment was for daily oral or weekly IV 6-mercaptopurine during consolidation.

72 minosalicylate drugs as well as azothiaprine/6-mercaptopurine during pregnancy.

73 (steroids and/or cyclosporine, azathioprine, 6-mercaptopurine, FK-506, methotrexate) were identified

74 ion therapy with the same combinations, plus 6-mercaptopurine, for 12 months total treatment.

75 aptopurine; however, patients assigned to IV 6-mercaptopurine had decreased survival after relapse.

76 6-mercaptopurine has been a standard component of long-t

77 The thiopurines azathioprine and 6-mercaptopurine have been extensively prescribed as imm

78 EFS was similar with oral or IV 6-mercaptopurine; however, patients assigned to IV 6-mer

79 icylates and 24.6% discontinued azathioprine/6-mercaptopurine in early pregnancy.

80 report our experience with azathioprine and 6-mercaptopurine in patients with microscopic colitis.

81 st potential benefit from the earlier use of 6-mercaptopurine in T-ALL therapy or the development of

82 N = 39) comparing methotrexate, azathioprine/6-mercaptopurine, infliximab, adalimumab, certolizumab,

83 In addition, 6-mercaptopurine is a clinically important pro-drug that

84 The purine anti-metabolite 6-mercaptopurine is one of the most widely used drugs fo

85 munosuppressant thiopurines, azathioprine or 6-mercaptopurine, is associated with acute skin sensitiv

86 purine methyl transferase and measurement of 6-mercaptopurine metabolites appear to be valuable for m

87 Studies of azathioprine and 6-mercaptopurine metabolites will make it easier and saf

88 of vincristine, adriamycin, prednisone, and 6-mercaptopurine (MP) and after continuous infusion of h

89 substitution of oral 6-thioguanine (TG) for 6-mercaptopurine (MP) and triple intrathecal therapy (IT

90 Recent studies of azathioprine/6-mercaptopurine, nitroimidazole antibiotics, and inflix

91 lower risk of isolated CNS relapse than did 6-mercaptopurine (odds ratio [OR] 0.53, 95% CI 0.30-0.92

92 ids (OR, 3.4; 95% CI, 1.8-6.2), azathioprine/6-mercaptopurine (OR, 3.1; 95% CI, 1.7-5.5), and inflixi

93 exposed to 5-aminosalicylates, azathioprine/6-mercaptopurine, or corticosteroids during their first

94 purine regulation of Nurr1 demonstrates that 6-mercaptopurine regulates Nurr1 through a region in the

95 A detailed analysis of 6-mercaptopurine regulation of Nurr1 demonstrates that 6

96 de, was a substrate, and it was converted to 6-mercaptopurine ribonucleotide.

97 metabolites, thiouric acid (TU) and 2-amino-6-mercaptopurine riboside (6-TGR).

98 6-mercaptopurine should remain the thiopurine of choice

99 A metabolite of AZA, 6-mercaptopurine, still possessed this antiviral effect,

100 S-adenosyl- l-homocysteine and the substrate 6-mercaptopurine, to 1.8 and 2.0 A resolution, respectiv

101 ance chemotherapy with oral methotrexate and 6-mercaptopurine was continued for 30 months.

102 wn that 6-thioguanine is more effective than 6-mercaptopurine, we compared the efficacy and toxicity

103 The prodrugs azathioprine and 6-mercaptopurine, which are well-established anticancer

104 rednisone and for intravenous (IV) over oral 6-mercaptopurine, which remain to be validated.

105 atient response to the chemotherapeutic drug 6-mercaptopurine, with some model parameters being patie